Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.57 by 19.3 percent. This is a 15.25 percent increase over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $3.80 billion which beat the analyst consensus estimate of $3.78 billion by 0.53 percent. This is a 2.81 percent decrease over sales of $3.91 billion the same period last year.
Teva Pharmaceutical Indus Q2 EPS $0.68 Beats $0.57 Estimate, Sales $3.80B Beat $3.78B Estimate
Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.57 by 19.3 percent. This is a 15.25 percent increase over earnings of $0.59 per share
Related Posts
Shiba Inu Sees Dramatic Surge In Network Growth Despite Repressed Prices Shows On-Chain Data
Shiba Inu token (CRYPTO: SHIB) on Wednesday, was one of the tokens accounting for the highest transaction fees.
What Happened: According to Santiment, an on-chain analytics platform, three key factors have contributed to the newfound optimism surrounding SHIB.
Regal Rexnord Announces Successful First Phase Of Financing For Proposed Acquisition Of Altra
Regal Rexnord Corporation (NYSE:RRX) today announced that it has completed the first phase of financing for its proposed acquisition of Altra Industrial Motion Corp. ("Altra"), by successfully amending its